Studies in this laboratory are designed to determine the effects of vasoconstrictor agents on the erectile response in rats. We have previously demonstrated that the vasoconstrictor effect of endothelin-1 (ET-1) is sharply reduced by erection and by nitric oxide (NO) administration. The present study was performed to determine if vasoconstriction, resulting from a-adrenergic stimulation, is altered by erection and NO. During continuous monitoring of corpus cavernosum pressure (CCP) and mean arterial pressure (MAP), erection was induced by electrical stimulation of the autonomic ganglion for the innervation of the penis. When the a-adrenergic agonist methoxamine (METH, 10 m mgakg) was injected before erection (ie, into the non-erect penis), the subsequent erectile response (CCPaMAP) was signi®cantly reduced from 0.68 AE 0.03 before METH to 0.34 AE 0.08 after METH. Injection of METH into the erect penis (ie, during erection) reduced the vasoconstrictor action of METH; CCPaMAP was 0.74 AE 0.02 before METH and 0.55 AE 0.05 after METH (P`0.05). The vasoconstrictor action of METH was slightly reduced when given in conjunction with NOR-1, a NO donor drug; CCPaMAP was 0.70 AE 0.05 before METH, 0.55 AE 0.09 after METH but this change was not signi®cant. These results demonstrate that the response to a aadrenergic stimulation is attenuated during erection in response to ganglionic stimulation. Furthermore, it appears that NO, produced during erection, may serve to override agonist-induced vasoconstriction. These results support our hypothesis that NO acts to directly stimulate relaxation of cavernous smooth muscle and to inhibit the vasoconstrictor actions of agents like ET-1 and a-adrenergic agonists including norepinephrine.
Introduction
It is widely accepted that nitric oxide (NO) is the principal agent that leads to relaxation of cavernosal smooth muscle of the penis and erection. 1 ± 4 The source of this NO is both the noncholinergicnonadrenergic innervation of the cavernous smooth muscle 5, 6 and the cavernosal endothelial cells. 7 However, NO-induced relaxation and penile erection are opposite to the prevailing state of the penis in which the cavernous smooth muscle contraction is maintained. When contracted, the rate of blood in¯ow is limited and intracavernosal pressures remain below the levels required to activate the veno-occlusive mechanism that limits out¯ow so the penis remains¯accid (non-erect). Contraction of the cavernous smooth muscle appears to be mediated by endothelin-1 (ET-1), 8 ± 11 norepinephrine 8, 12, 13 and possibly other vasoactive agents. 8, 14 However, there remains an unanswered question as to the interactions between the constrictive agents and the relaxation agents and how these interactions may change during erection. We have recently reported that the cavernous circulation is responsive to exogenously applied ET-1. 15 Blockade of ET A receptors prevented this ET-1 induced constriction and allowed intracavernosal pressure to rise during erection induced by ganglionic stimulation even after exogenous ET-1 administration. 15 Our studies also showed that the ET-1 induced vasoconstriction was signi®cantly diminished if it was injected into the cavernous sinuses during erection induced by autonomic stimulation or erection resulting from treatment with a NO donor drug. 16, 17 Based on these experiments, we suggested that NO may induce erection both by directly stimulating a cavernosal smooth muscle relaxation pathway and by overriding the vasoconstrictor effects of ET-1.
The role of the a-adrenergic system in the cavernosal circulation 18 and the interaction between norepinephrine and NO has received a recent review but remains an area of active investigation. 19 We have previously reported that intracavernosal injection of the a-adrenergic agonist (phenylephrine) caused a transitory decline in intracavernosal pressure and that this effect was signi®cantly greater in untreated-castrated rats than in testosterone treated-castrated rats. 20 Our prior studies also showed that in the absence of androgenic support, the synthesis of NO in the penis was diminished and erection was smaller. 21 These studies suggest a connection between NO and the a-adrenergic responsiveness of the penile tissue. The present study was undertaken to determine if NO alters the a-adrenergic responsiveness of the cavernosal circulation. We set out to determine if a-adrenergic-induced constriction is counteracted during ganglion-stimulation induced erection or erection resulting from the administration of a NO donor drug, NOR-1.
Materials and methods

Animals
Intact male Holtzman rats (Harlan Laboratories), 90 ± 120 days of age, were used in these studies. All procedures were performed in accordance with the Guiding Principles in the Care and Use of Animals established by the American Physiological Society and approved by the Medical College of Georgia Committee on the Use of Animals in Research and Education.
Measurement of the erectile response
We have previously described a method for measurement of corpus cavernosum pressure (CCP) and mean arterial pressures (MAP). 20 ± 23 In this method, rats were anesthetized with intramuscular ketamine (87 mgakg body weight) plus xylazine (13 mgakg) and maintained on supplemental ketamine as needed. The left carotid artery was cannulated for continuous monitoring of MAP. The shaft of the penis was freed of skin and fascia. The right corpus cavernosum was cannulated by insertion of a 30 gauge needle connected via PE tubing to a pressure transducer to permit continuous monitoring of CCP. The left corpus cavernosum was cannulated with 30 gauge needles attached to 10 ml syringes via short lengths of PE 10 tubing and used for administration (intracavernosal injection) of vasoactive drugs. The abdominal cavity was opened and the right major pelvic ganglion (MPG) exposed; stainless steel bipolar electrodes were positioned on the MPG and their position adjusted during stimulation until the maximal CCP was achieved. During the experiment, stimulatory voltages applied to the MPG ranged from 1 ± 5 V delivered in 5 ms pulses at a frequency of 12 Hz. The duration of stimulation was 1 or 2 min with rest periods of 5 ± 7 min between subsequent stimulations. All pressure data and stimulus duration were collected for analysis using Polyview data acquisition software (AstroMed, Grass Instrument Division).
Calculation of CCP and MAP
The Polyview data acquisition software continuously recorded CCP and MAP at a rate of 5 samplesas. Post-acquisition analysis utilized a mean function for obtaining an integrative mean CCP or MAP pressure over a desired time interval. Use of the mean pressure determination was valuable as the CCP displayed an oscillation during some of the ganglionic stimulations.
Experimental design
The designs of the experimental protocols are depicted in Figure 1 and described as follows:
Protocol 1: Effect of a-adrenergic stimulation with methoxamine (METH) before erection induced by ganglionic stimulation.
In this experiment, the MPG was stimulated for 2 min at 5 V to induce erection (before). After a rest period of 5 ± 7 min, METH was injected (10 or 40 mgaml) (METH). Two stimulations followed the METH administration at 3 and 7 min ( 3 min and 7 min) with a 2 min rest period between. A total of 10 animals were subjected to this protocol, ®ve for each dose of METH administered.
Protocol 2: Effect of a-adrenergic stimulation with methoxamine given during erection resulting from ganglionic stimulation.
The MPG was stimulated for 2 min at 5 V to induce erection (before). After a 5 ± 7 min rest period, the ganglionic stimulation was repeated and METH (10 or 40 mgaml) was injected into the left cavernous sinus 30 s after the start of the ganglionic stimulation (METH). The METH stimulation was then followed after a 2 min recovery by two more MPG stimulations 3 and 7 min later ( 3 min and 7 min) with a 2 min rest period between. A total of 11 animals were subjected to this protocol, NO suppression of adrenergic vasoconstriction CJ Wingard et al ®ve with the administration of 10 mgakg and six during administration of 40 mgakg of METH.
Protocol 3:
Effect of a-adrenergic stimulation with METH injected during erection resulting from intracavernosal administration of an NO donor drug. 1 ml ethanol vehicle was injected into the cavernous sinuses followed 2 min later by MPG stimulation (2 min at 5 V) resulting in erection (before). After a recovery period, NOR-1 (20 mgakg body weight) was injected in 1 ml ethanol. 2 min later, METH (10 mgakg) was injected so that the METH was administered during the NOR-1 induced increase in CCP (Nor METH). Three min after the NOR-1 injection, the MPG was stimulated to cause erection and this was followed by another stimulation 3 min later ( 3 min and 7 min) with a 2 min rest period between. A total of ®ve animals were subjected to this protocol.
Administration of 10 and 40 mgakg of METH was below the therapeutic doses of METH and phenylephrine used in the treatment of priapism. 24, 25 Saline vehicle injections had no effect on the erectile responses in any protocol. A separate set of animals was used for each protocol.
Drugs
METH was obtained from Sigma (St. Louis, MO).
was purchased from BIOMOL Research Laboratories, Inc (Plymouth Meeting, PA), dissolved in ethanol to prevent liberation of NO prior to injection. NOR-1 is stable when dissolved in an organic solvent but releases NO in an aqueous environment. 26 
Statistical analysis
Data were analyzed using analysis of variance for repeated measures with post hoc comparisons made by Student Newman Keuls test. 27 Student's tanalysis was used where appropriate. Statistical signi®cance was set at P`0.05. 
Results
The a-adrenergic agonist METH was selected for use in these studies because it has been characterized to have a longer half-life than norepinephrine and because it has high speci®city for the a 1A receptors. 28 Because of these properties, we were able to mimic the effects of sympathetic stimulation without having to continuously infuse a shorter acting a-adrenergic agonist such as norepinephrine or phenylephrine. Furthermore, a 1 -adrenergic receptors are abundant in smooth muscle cells of the cavernous circulation. 28 ± 30 The erectile response (CCPaMAP) during stimulation of the MPG between 1 ± 5 V is shown in Figure  2 . This ®gure demonstrates that with increasing voltage (1 ± 5 V), there is a signi®cant increase in the The results in Figure 3 illustrate the change in CCP following METH administration (10 or 40 mgakg) before the stimulation of the MPG. Corpus cavernosal pressure was markedly reduced at both doses suggesting that METH caused constriction of the arteriolar and sinusoidal smooth muscle to limit in¯ow. Displayed in Figure 3A is a representative trace of the CCP and MAP during a protocol in which 10 mgakg of METH was introduced into the cavernosal sinuses prior to MPG stimulation. The MAP was relatively unaffected by the a-adrenergic agonist at either dose as depicted in this panel. The mean erectile responses are summarized in panels 3B and C. The erectile response following METH administration was signi®cantly suppressed compared to the initial control response and showed only partial recovery with the subsequent stimulatons for both the 10 and 40 mgakg METH administrations.
To determine if MPG-stimulated erection itself altered the responsiveness to a-adrenergic vasoconstriction, 10 or 40 mgakg METH was injected during 
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CJ Wingard et al MPG-stimulated erections. As represented in Figure  4A , when METH (10 mgakg) was administered during erection, the subsequent CCP response was not suppressed to the same extent as was seen when METH was injected before MPG-stimulated erection ( Figure 3A) . Panels 4B and C represent the mean erectile responses following administration of METH during MPG-stimulation. While the erectile responses were lower than the before they were nearly identical to each other across the three stimulations. The METH effect resulted in a diminished erectile response of only 27.1% after 10 mgakg or 46.9% after 40 mgakg when injected during MPGstimulated erection as compared to 88.1% after 10 mgakg or 90.5% after 40 mgakg when administered before MPG-stimulation induced erection.
In an effort to examine if the mediator of the suppression of the erectile response by METH induced vasoconstriction was NO, released during MPG stimulation, we used the NO donor drug NOR-1 to prevent the observed METH suppression of erectile response. Preliminary studies showed that injection of NOR-1 into the cavernous sinuses did not augment the erectile response induced by maximal stimulation of the MPG. Figure 5A reveals that when injected during NOR-1 induced erection, METH failed to exhibit its strong vasoconstrictor effects on subsequent erections. In these Reported are the means AE 1 s.e.m. of ®ve rats. *Indicates statistical signi®cance as compared to the before value (P`0.05).
NO suppression of adrenergic vasoconstriction CJ Wingard et al experiments, NOR-1 (20 mgakg) was injected into the cavernous sinuses and 1 min later, when the CCP had started to rise, METH (10 mgakg) was injected into the sinuses. Panel 5B summarizes the erectile responses and illustrates, when injected during NO induced erection, the vasoconstrictor effect of METH on subsequent MPG-stimulated erections was signi®cantly diminished and not different from the before value at 3 and 7 min erections. Figure 6 summarizes the CCPaMAP responses from the different experimental protocols in which METH (10 mgakg) was administered before erection, during erection induced by MPG stimulation and during erection resulting from the administration of the NO donor drug NOR-1. In this ®gure, the erectile responses after METH are expressed as the percentage of the responses measured before METH administration. Injection of METH (10 mgakg) signi®cantly decreased the erectile response by 55.4% when given before erection. However, when administered during erection, resulting from MPG stimulation or resulting from administration of the NOR-1, the vasoconstrictive effect of METH (10 mgakg) was diminished by only 24.6% and 15.0%, respectively.
Discussion
In this study we report a differential erectile response during the administration of the speci®c a1-adrenergic agonist, METH. Administration of METH prior to an erection suppressed the subsequent erection by more than 50%. When administered during an erection induced by either stimulation of the MPG or by injection of the NO donor drug NOR-1 METH suppressed the subsequent erections by $ 20%. This observed disparity in the erectile response suggests an antagonism of action between the vasoconstrictor METH and the vasodilator NO in the cavernosal circulation during ganglionic stimulation. The physiologic antagonism that appears to exist between the NO mediated vasorelaxation of cavernosal smooth muscle and the aadrenergic stimulated contraction has been recently reviewed. 18, 19 Cellek postulated that the antagonism of NOanorepinephrine interactions likely occurs at the level of the cavernosal smooth muscle cells as there is no evidence that NO and norepinephrine are released from the same neurons. 19 Andersson also suggested parasympathetic activity could relax penile smooth muscle by two mechanisms, both of which reduced the effectiveness of the vasoconstrictive actions of norepinephrine. These mechanisms would include inhibition of norepinephrine release by stimulation of muscarinic receptors on the adrenergic terminals or a post-junctional effect which counteracts the release of NO or another relaxation factor from the endothelium. 5 The antagonism of action has been thought to be a result of an action of NO to alter neurotransmitter release. 31, 32 Others have shown that either exogenous or endogenous NO could reduce or modulate the responsiveness of a 1 -adrenoreceptors without affecting neurotransmitter release. 19, 33, 34 Furthermore, NO does not appear to affect the amount of norepinephrine released by the sympathetic innervation of the penile circulation in the rabbit and human. 19 Despite this, however, the NO system appears to regulate fully the responsiveness to aadrenergic stimulation in some smooth muscles of Figure 6 Comparison of the summary effects of METH on the erectile response (CCPaMAP) when administered before erection or during erections resulting from MPG-stimulation or injection of the NO donor drug NOR-1. The results are expressed relative to the erectile response elicited by MPG-stimulation prior to the administration of 10 mgakg METH. Bars represent the mean AE 1 s.e.m. of 5 ± 6 measurements. *Indicates signi®cant decrease in the erectile response based on ANOVA for repeated measures (P`0.05).
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CJ Wingard et al the genitourinary system. 1 These reports and the results of the present study support a role for NO in modulating the predominance of the a 1 -adrenergic vasoconstrictive pathway. These results suggest that when NO is elevated either by ganglionic stimulation or the use of a NO donor, the vasoconstrictive action of METH was blunted. This is in addition to the well-described role of NO in activating alternative relaxation pathways which impacts the calcium handling properties of smooth muscle. 35 a-Adrenergic stimulation may also impact the release or action of NO leading to a reduction in the erectile response. This observation is supported by a recent report of Simonsen and co-workers. They found that release of norepinephrine might cause suppression of NO release via stimulation of prejunctional a 2 -adrenoreceptors in penile resistance arteries. 36 Thus with the administration of METH a mechanism which reduces NO responsiveness may be activated and the erectile response reduced.
Prior studies from this laboratory have investigated the actions of another vasoconstrictor in the cavernosal circulation. 15, 20 In those experiments, we reported that injection of ET-1 caused vasoconstriction and reduced the magnitude of subsequent erections. This vasoconstrictor action of ET-1 was blocked by prior administration of an antagonist speci®c to the ET A receptor; administration of an antagonist to the ET B receptor had no effect on the cavernosal response to ET-1. Furthermore, if ET-1 was injected during erection by MPG stimulation or erection resulting from administration of a NO donor drug, the vasoconstrictor action of ET-1 was largely blocked. 16, 17 Taken together, these studies show that the actions of two major vasoconstrictor pathways in the penile circulation, which maintain the penis in the¯accid state, are inhibited during periods of elevated NO. This ®nding may help to explain how penile erection can occur in the presence of potent vasoconstrictive agents like norepinephrine and ET-1. Furthermore, an imbalance in the physiological antagonism between NO on one hand, and norepinephrine and ET-1 on the other hand, could help to explain the etiology of some types of erectile dysfunction. 19 The ®nding may also explain the results of Mills and co-workers who demonstrated a reduction in the magnitude of the erectile response to stimulation of the MPG among castrated rats vs animals receiving testosterone replacement. 20 They postulated that part of the reduction in erectile function in the castrated animals was due to an increased sensitivity to a-adrenergic stimulation although NO production in the castrated animals was de®cient as well. 21 These published observations along with the ®ndings of the present study seem to offer an explanation for the reduced erectile response in the castrated animals. With reduced NO production in the castrates, there would be less inhibition of the vasoconstrictors and a reduced erectile response.
The results of the present study support the hypothesis that NO modulates the contractile state of smooth muscle in the erectile vasculature. Our results show that the intracavernosal injection of METH leads to a marked reduction in the magnitude of subsequent erections. Furthermore, if the same dose of METH is injected during erection resulting from ganglionic stimulation or from injection of a NO-donor drug, the vasoconstrictor action of METH is sharply diminished. Thus, erection resulting from endogenous or exogenous applied NO overrides the vasoconstrictor action of the a-adrenergic agonist.
